User reports of feeling more refreshed despite similar sleep duration suggest improved sleep quality including potentially better REM sleep

Case Study #3: Athletic Performance Optimization Patient: 38-year-old male competitive age-group triathlete Chief Complaints: Declining recovery between training sessions, persistent low-grade injuries, inability to hit previous power numbers despite consistent training Baseline Assessment: IGF-1: 168 ng/mL (suboptimal for training load) Testosterone: 512 ng/dL (adequate but not optimal for performance goals) hs-CRP: 2.1 mg/L (chronic low-grade inflammation) Ferritin: 32 ng/mL (suboptimal for endurance athlete) Training metrics: 7-day recovery time after hard sessions (goal: 2-3 days) Treatment Protocol: Foundation: Address iron deficiency with supplementation, optimize nutrition timing around training Hormone optimization: Testosterone enanthate to achieve 850-950 ng/dL range Peptide therapy: Sermorelin 400 mcg nightly, 6 nights/week (timed around training schedule) Supporting interventions: Sleep optimization protocol, targeted anti-inflammatory nutrition 16-Week Results: IGF-1: 284 ng/mL (+69%) Recovery time: 2-3 days for hard sessions (71% improvement) FTP (functional threshold power): +18 watts Body composition: -2.1% body fat, +1.9 kg lean mass hs-CRP: 0.6 mg/L (normalized) Race results: Two age-group podiums in half-iron distance races Patient Report: The recovery improvement is dramatic

Weight Loss Effect of Moringa When it comes to moringa and weight loss, there are some indications in the existing evidence that the plant could help
Clinical trials have shown tirzepatide producing greater average weight loss than semaglutide approximately 20-22% total body weight versus 15% though both represent significant advances in pharmacological weight management
The results highlight the need for more personalised approaches to prescribing these widely used medications, which are also used for weight-loss
This injectable fits the bill The company said it had received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market the drug, following a clinical comparison study